A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2 vector

Sci Rep. 2019 Sep 9;9(1):12901. doi: 10.1038/s41598-019-49579-y.


Ectopic protein with proper steric structure was efficiently loaded onto the envelope of the F gene-defective BC-PIV vector derived from human parainfluenza virus type 2 (hPIV2) by a reverse genetics method of recombinant virus production. Further, ectopic antigenic peptide was successfully loaded either outside, inside, or at both sides of the envelope of the vector. The BC-PIV vector harboring the Ebola virus GP gene was able to elicit neutralizing antibodies in mice. In addition, BC-PIV with antigenic epitopes of both melanoma gp100 and WT1 tumor antigen induced a CD8+ T-cell-mediated response in tumor-transplanted syngeneic mice. Considering the low pathogenicity and recurrent infections of parental hPIV2, BC-PIV can be used as a versatile vector with high safety for recombinant vaccine development, addressing unmet medical needs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / immunology
  • Chlorocebus aethiops
  • Epitopes / genetics
  • Epitopes / immunology
  • Gene Order
  • Genetic Engineering
  • Genetic Vectors / genetics*
  • Humans
  • Mice
  • Neutralization Tests
  • Parainfluenza Virus 2, Human / genetics*
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocyte Subsets / metabolism
  • Vaccines, Synthetic / genetics*
  • Vaccinology / methods*
  • Vero Cells


  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Epitopes
  • Vaccines, Synthetic